TABLE OF CONTENTS

5 EXECUTIVE SUMMARY
7 COMPANY CONTEXT
7 Vision 2020
7 Vision 2025 streamlined approach
7 Inorganic growth in emerging markets
8 Intensive collaboration and partnership strategy
8 Oncology
8 Takeda’s SWOT analysis
9 Takeda’s key events and catalysts
11 FACTS AND FIGURES
11 Takeda’s prescription pharma sales outlook
11 Takeda’s therapy area dynamics
15 Takeda’s top 10 products over 2016–26
15 Takeda’s growth drivers and resistors
21 Takeda’s launch/core/expiry analysis
23 Takeda’s M&A history
27 KEY THERAPY AREAS
27 Oncology
33 Gastroenterology
35 Immunology and inflammation
38 Central nervous system
41 ABOUT THIS REPORT
41 Analysis structure
41 Bibliography

LIST OF FIGURES
11 Figure 1: Takeda’s prescription pharmaceutical sales ($m) and growth rate (%), 2013–26
12 Figure 2: Takeda’s therapy area dynamics, 2016–26
15 Figure 3: Takeda’s top 10 product sales ($m), 2016–26
21 Figure 4: Takeda’s launch/core/expiry portfolio configuration, 2016–26

LIST OF TABLES
13 Table 1: Takeda’s sales by therapy area ($m), 2016–26
16 Table 2: Takeda’s key products, 2016–26
22 Table 3: Takeda’s sales by launch, core, and expiry portfolio ($m), 2016–26
24 Table 4: Takeda’s key merger and acquisition deals, 2005–17
28 Table 5: Takeda’s oncology portfolio ($m), 2016–26
34 Table 6: Takeda’s gastroenterology portfolio ($m), 2016–26
36 Table 7: Takeda’s immunology and inflammation portfolio ($m), 2016–26
39 Table 8: Takeda’s central nervous system portfolio ($m), 2016–26